2023
Antihypertensives in Pregnancy
Denoble A, Goldstein S, Pettker C. Antihypertensives in Pregnancy. Obstetrics And Gynecology Clinics Of North America 2023, 50: 39-78. PMID: 36822710, DOI: 10.1016/j.ogc.2022.10.008.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsSignificant maternal morbidityTreatment of hypertensionAmniotic fluid volumeHypertensive disordersMaternal morbidityPregnant patientsFetal growthCurrent guidelinesEfficacy dataAvailable safetyPregnancyAntihypertensivesFluid volumeClose supervisionHypertensionMorbidityPatientsPostpartumMortalityAvailable dataDiagnosis
2021
AGE AND LOCATION OF DEATH DIFFER IN ADULT PATIENTS WITH CONGENITAL HEART DISEASE COMPARED WITH THE GENERAL POPULATION
Goldstein S, Kumar P, Shahid I, Serfas J, Krasuski M, Khan M, Krasuski R. AGE AND LOCATION OF DEATH DIFFER IN ADULT PATIENTS WITH CONGENITAL HEART DISEASE COMPARED WITH THE GENERAL POPULATION. Journal Of The American College Of Cardiology 2021, 77: 489. DOI: 10.1016/s0735-1097(21)01848-9.Peer-Reviewed Original Research
2020
Implantable Cardioverter Defibrillator Utilization and Mortality Among Patients ≥65 Years of Age With a Low Ejection Fraction After Coronary Revascularization
Goldstein S, Li S, Lu D, Matsouaka R, Rymer J, Fonarow G, de Lemos J, Peterson E, Pokorney S, Wang T, Al-Khatib S. Implantable Cardioverter Defibrillator Utilization and Mortality Among Patients ≥65 Years of Age With a Low Ejection Fraction After Coronary Revascularization. The American Journal Of Cardiology 2020, 138: 26-32. PMID: 33068540, DOI: 10.1016/j.amjcard.2020.09.056.Peer-Reviewed Original ResearchMeSH KeywordsAftercareAge FactorsAgedAged, 80 and overCardiologyCoronary Artery BypassDeath, Sudden, CardiacDefibrillators, ImplantableFemaleHeart FailureHumansMaleMedicareMortalityMyocardial InfarctionMyocardial RevascularizationPatient ReadmissionPercutaneous Coronary InterventionProportional Hazards ModelsSex FactorsStroke VolumeTachycardia, VentricularUnited StatesVentricular FibrillationConceptsImplantable cardioverter-defibrillator implantationImplantable cardioverter-defibrillatorIn-hospital ventricular arrhythmiasLow ejection fractionAssociated with ICD implantationEjection fractionVentricular arrhythmiasICD implantationCoronary revascularizationCABG-treated patientsPCI-treated patientsAssociated with lower mortalityCardiology follow-upIn-hospital revascularizationAll-cause mortalityAssociated with higher likelihoodICD utilizationHeart failure readmissionHeart failureYear of revascularizationCardioverter-defibrillatorRevascularization strategyMedicare claimsRevascularizationPatientsCauses of Death and Cardiovascular Comorbidities in Adults With Congenital Heart Disease
Goldstein S, D’Ottavio A, Spears T, Chiswell K, Hartman R, Krasuski R, Kemper A, Meyer R, Hoffman T, Walsh M, Sang C, Paolillo J, Li J. Causes of Death and Cardiovascular Comorbidities in Adults With Congenital Heart Disease. Journal Of The American Heart Association 2020, 9: e016400. PMID: 32654582, PMCID: PMC7660712, DOI: 10.1161/jaha.119.016400.Peer-Reviewed Original ResearchConceptsCongenital heart diseaseSevere congenital heart diseaseMedian ageNonsevere CHDPresence of cardiovascular comorbiditiesHeart diseaseCardiovascular risk factorsNon-CHD causesIschemic heart diseaseElectronic medical record dataDeath certificate dataCause of deathNonsevere diseaseContemporary cohortValvular lesionsCardiovascular comorbidityCardiovascular comorbiditiesResults PatientsCardiovascular deathMedical record dataRisk factorsSevere groupLesion severityPatientsCertificate data
2019
Complications involving the subcutaneous implantable cardioverter-defibrillator: Lessons learned from MAUDE
Zeitler E, Friedman D, Loring Z, Campbell K, Goldstein S, Wegermann Z, Schutz J, Smith N, Black-Maier E, Al-Khatib S, Piccini J. Complications involving the subcutaneous implantable cardioverter-defibrillator: Lessons learned from MAUDE. Heart Rhythm 2019, 17: 447-454. PMID: 31561032, PMCID: PMC7519585, DOI: 10.1016/j.hrthm.2019.09.024.Peer-Reviewed Original ResearchConceptsSubcutaneous implantable cardioverter-defibrillatorS-ICD complicationsImplantable cardioverter-defibrillatorS-ICDInappropriate shocksCardioverter-defibrillatorSystem removalLow rate of complicationsProcedure-related complicationsRate of complicationsFood and Drug Administration's ManufacturerManufacturer and User Facility Device ExperienceUser Facility Device ExperiencePatient selectionFollow-upComplicationsTransvenous devicesVentricular fibrillationDevice-device interactionsClinical experiencePatientsDefibrillation failureImplantation techniqueSystem reprogrammingSystem revisionCharacteristics and Outcomes of Atrial Fibrillation in Patients With Thyroid Disease (from the ARISTOTLE Trial)
Goldstein S, Green J, Huber K, Wojdyla D, Lopes R, Alexander J, Vinereanu D, Wallentin L, Granger C, Al-Khatib S. Characteristics and Outcomes of Atrial Fibrillation in Patients With Thyroid Disease (from the ARISTOTLE Trial). The American Journal Of Cardiology 2019, 124: 1406-1412. PMID: 31474328, PMCID: PMC7194994, DOI: 10.1016/j.amjcard.2019.07.046.Peer-Reviewed Original ResearchConceptsThyroid disease historyThyroid diseaseAtrial fibrillationDisease historyThromboembolic eventsClinical outcomesOutcomes of atrial fibrillationHistory of thyroid diseaseBaseline characteristics of patientsCox modelBenefits of apixabanOther Thromboembolic EventsCharacteristics of patientsEffects of anticoagulantsAdjusted hazard ratiosBaseline characteristicsCompare outcomesHazard ratioThyroidApixabanPatientsRandomized treatmentWarfarinHypothyroidismDisease
2018
Timing of cardiac resynchronization therapy device implantation in heart failure patients and its association with outcomes
Goldstein S, Mentz R, Hellkamp A, Randolph T, Fonarow G, Hernandez A, Yancy C, Al‐Khatib S. Timing of cardiac resynchronization therapy device implantation in heart failure patients and its association with outcomes. Clinical Cardiology 2018, 42: 256-263. PMID: 30548280, PMCID: PMC6386168, DOI: 10.1002/clc.23135.Peer-Reviewed Original ResearchConceptsCardiac resynchronization therapy implantationCardiac resynchronization therapyHF re-hospitalizationHeart failureRe-hospitalizationHF hospitalizationCardiac resynchronization therapy device implantationOutcome of all-cause mortalityTime of CRT implantationAssociated with clinical outcomesAssociated with similar benefitsAll-cause mortalityAssociated with lower ratesHeart failure patientsCRT implantationResynchronization therapyClinical outcomesHF patientsDevice implantationFailure patientsCenters for MedicarePatientsDelayed implantationReduce mortalityMedicaid Services data
2017
The Use of Implantable Cardioverter-defibrillators in the Prevention of Sudden Cardiac Death: A Focus on Congenital Heart Disease and Inherited Arrhythmia Syndromes
Goldstein S, Ward C, Al-Khatib S. The Use of Implantable Cardioverter-defibrillators in the Prevention of Sudden Cardiac Death: A Focus on Congenital Heart Disease and Inherited Arrhythmia Syndromes. Journal Of Innovations In Cardiac Rhythm Management 2017, 9: 2996-3005. PMID: 32494470, PMCID: PMC7252881, DOI: 10.19102/icrm.2018.090103.Peer-Reviewed Original ResearchCongenital heart diseaseInherited arrhythmia syndromesSudden cardiac deathArrhythmia syndromesCardiac deathIncreased risk of sudden cardiac deathPrevention of sudden cardiac deathRisk of sudden cardiac deathHeart diseaseImplantable cardioverter-defibrillator (ICDCardioverter-defibrillator (ICDRisk stratification methodsNon-randomized studiesImplantable cardioverter-defibrillatorRandomized clinical trialsCardioverter-defibrillatorClinical trialsIncreased riskPatientsSyndromeDiseaseImplantationStratification methodICDDeath